Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EML4 | Q9HC35 | 8/20 | 0.48 |
| ▸ | ALK | Q9UM73 | 8/20 | 0.48 |
| ▸ | RET | P07949 | 8/20 | 0.46 |
| ▸ | ROS1 | P08922 | 8/20 | 0.46 |
| ▸ | FLT3 | P36888 | 8/20 | 0.46 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.44 |
| ▸ | CDK2 | P24941 | 2/20 | 0.44 |
| ▸ | AURKA | O14965 | 1/20 | 0.44 |
| ▸ | CDK4 | P11802 | 1/20 | 0.44 |
| ▸ | CCND3 | P30281 | 1/20 | 0.44 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.44 |
| ▸ | SYK | P43405 | 6/20 | 0.42 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.42 |
| ▸ | MAPKAPK5 | Q8IW41 | 1/20 | 0.40 |
| ▸ | LCK | P06239 | 1/20 | 0.40 |
| ▸ | JAK3 | P52333 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24944378 | 0.97 | EML4 (0.46) | EML4ALKRETROS1FLT3 | |
| SCHEMBL24944782 | 0.93 | RET (0.49) | EML4ALKRETROS1FLT3 | |
| SCHEMBL29173582 | 0.93 | PIM1 (0.41) | EML4ALKRETROS1FLT3 | |
| SCHEMBL24943805 | 0.91 | EML4 (0.58) | EML4ALKRETROS1FLT3 | |
| SCHEMBL30205518 | 0.91 | EML4 (0.58) | EML4ALKRETROS1FLT3 | |
| SCHEMBL30206202 | 0.91 | PKMYT1 (0.40) | EML4ALKRETROS1FLT3 | |
| SCHEMBL29173512 | 0.91 | PKMYT1 (0.40) | EML4ALKRETROS1FLT3 | |
| SCHEMBL24944959 | 0.91 | EML4 (0.45) | EML4ALKRETROS1FLT3 | |
| SCHEMBL24944729 | 0.91 | EML4 (0.45) | EML4ALKRETROS1FLT3 | |
| SCHEMBL30205764 | 0.91 | EML4 (0.45) | EML4ALKRETROS1FLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4373817-B1 | SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2025-05-21 | — | — | EP | claimed |
| EP-4373817-A1 | SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER | Astrazeneca AB (SE) | 2024-05-29 | — | — | EP | claimed |
| CN-117693503-A | Substituted pyrazine-2-carboxamides as HPK1 inhibitors for the treatment of cancer | 阿斯利康(瑞典)有限公司 | 2024-03-12 | — | — | CN | claimed |
| WO-2023001794-A1 | SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2023-01-26 | — | — | WO | claimed |
| EP-4373817-A1 | SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER | Astrazeneca AB (SE) | 2024-05-29 | — | — | EP | disclosed |
| CN-117693503-A | Substituted pyrazine-2-carboxamides as HPK1 inhibitors for the treatment of cancer | 阿斯利康(瑞典)有限公司 | 2024-03-12 | — | — | CN | disclosed |
| WO-2023001794-A1 | SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2023-01-26 | — | — | WO | disclosed |
| WO-2023001794-A1 | SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2023-01-26 | — | — | WO | disclosed |